Day: December 20, 2021

These portable monitors promise to enable productivity and collaboration with enhanced touchscreen capabilities

At just 5.3 mm thin and created from a single piece of aluminium, espresso Displays can be powered directly from a device and can be set up in seconds. With AutoRotation available across the range, users can instantly adjust their content between landscape and profile formats.

“Our new range of portable monitors are like nothing else on the market. They’re incredibly thin, deliver amazing picture quality, and are compatible with just about any device, platform or software on the market,” said Will Scuderi, espresso CEO and Co-founder. “espresso products are designed to transform how people think about performing at their best, at any time and in any environment, regardless of their device or what they need to get done.”

espresso has developed unique software, espressoFlow, to integrate its touch features with Mac and Windows users who seek a smooth and more intuitive experience with applications and software. espressoFlow enables the touch experience across applications like Adobe CC, Figma, Miro and Asana.

espresso touch displays are also enhanced with Palm Rejection functionality, a feature designed to support and optimise creative tasks.

“Every feature has been designed to help people optimise user’s workflow by adapting to their unique ways of working,” Scuderi added.

To support the launch of the new product range, the espresso Display brand identity has been updated and refreshed. The impactful positioning of ‘More. Anywhere.’ serves to support customers anywhere they need to be to develop their best selves.

• espresso Display 15 touch is the pinnacle of innovation by espresso with a rich and immersive screen.
• espresso Display 13 touch is a compact powerhouse with everything espresso innovation has to offer.
• espresso Display 13 offers the foundations of espresso’s premium design and intuitive functionality.
• espressoStand: Portability and productivity come together in seconds with the espresso stand.
• espressoCase: The case not only effectively protects the screen but it easily converts into a display stand.
• espressoMount: The espressoMount can be set up quickly with a VESA arm.
• espressoPen: Unleash your creativity and enhance your collaboration using our customised pen.

Pricing and availability:

The three new espresso Display models and accessories will be available for pre-sale from 20 December 2021 with shipments commencing in January 2022. espresso is available in the USA, Europe, UK and Australia.

The Displays start from $339 USD up to $499 USD and are available on the official espresso website.

Learn more about our products here.

Press Inquiries Contact:
Clare O’Rourke – PR Manager
Email: clare@espres.so

Related Files

wordmark150@2x.png

Related Images

Image 1: espresso Display

Display 15 Touch enables collaboration and productivity.

Image 2: Display V2

This content was issued through the press release distribution service at Newswire.com.

Attachment

• espresso Display

Open to the public, this highly anticipated digital party will be held on Thursday, December 23, at 10 a.m. EST (3 p.m. GMT), taking place on a large temple-inspired stage built on ‘Cryptovoxels’, and will bring Steve Aoki’s DJ set to the Metaverse to celebrate the holidays.

The digital celebration intends to commemorate the monumental growth of Monkey Kingdom, the first-of-its-kind NFT project originating from Asia. Since its recent launch on the Solana platform on Nov. 27, 2021, Monkey Kingdom has grown to become one of the most successful NFT networks in the world, exhibiting a remarkable upward trajectory seldom achieved by the majority of NFT projects on any platform today.

“In the early days of my DJ career, I toured extensively in Asia, building a strong fan base for my music and was a key pillar to building my musical career. I’ve been collecting NFTs for some time now, and as an owner of several Monkey Kingdom NFTs, I was thrilled to witness an NFT project originating from Asia to make such an impact globally in a relatively short timeframe,” says Steve Aoki. “I am excited to share my music with the Monkey Kingdom community, and I hope this special movement encourages more creators from Asia to get more involved in growing Asian representation in this space.”

Monkey Kingdom consists of 2,222 algorithmically generated NFTs inspired by the legendary Monkey King, Sun Wukong, the iconic protagonist in the 16th-century novel Journey to the West. Best known for his supernatural abilities and whimsical escapades, Sun Wukong is a cultural emblem symbolizing wisdom, optimism, and perpetual youth, and is widely recognized within global Asian communities.

Originally created to bring an Asian voice to the incredibly fast-growing NFT market, Monkey Kingdom has already garnered the support of prominent global celebrities and cultural personalities of Asian descent, including Steve Aoki (DJ and Producer), JJ Lin (Singer), Sunny Wang (Actor), Dizzy Dizzo (Musician), Ian Chan (from Hong Kong-based boy band Mirror), Dr. Woo (Tattoo artist), and Verbal (Japan-based musician and CEO of fashion brand AMBUSH), to name a few.

Additionally, Monkey Kingdom will be minting ‘Baepes‘, a collection of 2,221 female Wukongs, on Dec. 21, 2021. To further support Monkey Kingdom’s vision of building a global NFT community supporting Asian creativity, all minting proceeds will be donated to the Asia Society, a non-profit organization that seeks to forge closer ties between Asia and the West through arts, education, policy and business outreach.

Monkey Kingdom NFT holders and members of the Cryptovoxels community around the globe are invited to attend the Metaverse X’Mas Party. To attend the digital party, please visit https://party.monkeykingdom.io.

For more information on Monkey Kingdom, please visit:

www.monkeykingdom.io

magiceden.io/marketplace/monkey_kingdom

Instagram and Twitter: @monkeykingdom_

Media Contact: jessica@tylerbarnettpr.com

Related Images

Image 1: Steve Aoki x Monkey Kingdom Metaverse X’Mas Party

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Steve Aoki x Monkey Kingdom Metaverse X’Mas Party

Milan, Dec. 20, 2021 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it has won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham). The company was named the 2021 winner for its investments in the Italian biopharmaceutical industry, which includes expansion at its Center of Excellence in Milan to make it a global hub for cell and gene therapy innovation, development and manufacturing.

The annual award honors companies fostering economic development and growth between Italy and the United States. Luca Alberici, AGC Biologics General Manager and Site Head of the Milan facility, received the award on behalf of the company during the XV Transatlantic Award Gala Dinner, held on December 2 at Studio 90 East End Studios in Milan.

The additional guests of honor at the award ceremony included Mariangela Zappia (AmCham Italy Honorary President and Ambassador of Italy to the United States of America), Thomas D. Smitham (Chargé d’Affaires and interim and U.S. Embassy to Italy), On. Giancarlo Giorgetti (Italian Minister of Economic Development) and On. Lorenzo Guerini (Italian Minister of Defense).  AGC Biologics was honored alongside other notable companies such as Apple, Coca-Cola, Diasorin and KKR.

“I am happy and honored to receive this award on behalf of AGC Biologics. This is an important award that showcases the investments our company has made in our Milan site, as well as the growing biopharmaceutical industry in our region,” said AGC Biologics Milan General Manager and Site Head, Luca Alberici. “Our Center of Excellence, one of the best in world and our team of scientists and employees, who work hard every day with responsibility and professionalism, played a crucial role in the successes we’ve achieved over the last two years.”

AGC Biologics acquired the Milan facility when it purchased Molecular Medicine S.p.A. (“MolMed”) in 2020. Since that transaction, AGC Biologics has focused on supporting and developing the teams working at the site, and investing in expanding the site’s services, capabilities and production capacities. These commitments in the Milan facility have helped AGC Biologics become one of the most complete and active biotech CDMOs in the global healthcare market.

The AGC Biologics Milan site was the first GMP facility approved in Europe for ex-vivo gene therapy manufacturing and has industry-unique commercial manufacturing experience, having previously brought three cell & gene therapy products to the market.

To complement the Center of Excellence in Milan, the company recently opened a new facility in Longmont, CO., USA, which will help AGC Biologics expand its global capacity for cell and gene therapy development and manufacturing. Through these two key sites, AGC Biologics can now offer more capacity and services to pharmaceutical companies worldwide developing new life-changing cell and gene therapy products.

About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

Nick McDonald
AGC Biologics
(425) 419-3555
nmcdonald@agc.com

Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada

Lugano, Switzerland, and Mississauga, Ontario, 20 December 2021 – Helsinn Group (Helsinn), a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market potential, and Xediton Pharmaceuticals Inc. (Xediton), a Canadian based specialty pharmaceutical company with a strong presence in products in Oncology, announced today the signing of an exclusive license and distribution agreement in Canada for TRUSELTIQ™ (infigratinib), which was recently approved under Health Canada’s Notice of Compliance with Conditions (NOC/c) policy for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.

Under the terms of the license and distribution agreement, Helsinn Healthcare SA grants Xediton an exclusive license to distribute, promote, market, and sell TRUSELTIQ in Canada and Helsinn will supply TRUSELTIQ for commercialization in Canada. TRUSELTIQ has been reviewed in Canada under Project Orbis, an initiative of the U.S. Food and Drug Administration’s (FDA’s) Oncology Center of Excellence that allows for concurrent submission and review of oncology drugs among participating international regulatory agencies.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO commented, “We are very pleased to have signed this agreement with Xediton for the distribution of TRUSELTIQ in Canada. This marks an important step in our TRUSELTIQ commercialization strategy. We look forward to continuing to work closely with Xediton to ensure that this treatment reaches the Canadian patients that could most benefit from it.”

George Gafrey, President of XEDITON Pharmaceuticals Inc., commented: “We are very pleased to partner with Helsinn Group to bring to Canadian patients TRUSELTIQ. We believe TRUSELTIQ and its imminent launch will fill a gap in the much-needed therapy for cancer patients. We look forward to TRUSELTIQ being on the market.”

About TRUSELTIQ™ (infigratinib)

TRUSELTIQ (infigratinib) is a small molecule kinase inhibitor that targets FGFR, which was conditionally approved by Health Canada for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.

Prior to initiation of TRUSELTIQ therapy, FGFR2 fusion or rearrangement should be established using a validated test.

Clinical effectiveness of TRUSELTIQ is based on overall response rate (ORR) and duration of response (DoR) from a single-arm Phase 2 trial in patients with specific FGFR2 fusion or other rearrangements.

Infigratinib is not FDA- or Health Canada-approved for any other indication in the United States and Canada.

About Cholangiocarcinoma (CCA)

CCA (bile duct cancer) represents an aggressive group of malignancies that form in the bile ducts. The incidence of this serious and fatal disease varies considerably worldwide. As the disease is usually asymptomatic at early-stages, CCA typically presents at diagnosis as locally advanced or metastatic disease with a poor prognosis. FGFR2 genetic aberrations are present in approximately 15% to 20% of people who have this disease. Currently, the five-year survival rate is only 9%.¹

References

¹ Dhanasekaran, R., Hemming, A. W., Zendejas, I., George, T., Nelson, D. R., Soldevila-Pico, C., Firpi, R. J., Morelli, G., Clark, V., Cabrera, R. “Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma”. Oncology Reports 29.4 (2013): 1259-1267.

TRUSELTIQ is a trademark of Helsinn Group.

About the Helsinn Group

Helsinn is a fully integrated, global biopharma company headquartered in Lugano, Switzerland. It is focused on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and innovative pipeline of cancer therapeutics.

Helsinn is a third-generation family-owned company, that since 1976 has been focused on improving the lives of patients, guided by core values of respect, integrity and quality. It operates a unique licensing business model with integrated drug development and manufacturing capabilities. Helsinn has a commercial presence in over 190 countries either directly, with operating subsidiaries in the U.S. and China, or via its network of long-standing trusted partners.

Helsinn plays an active and central role in promoting social transformation in favor of people and the environment. Corporate social responsibility is at the heart of everything we do, which is reinforced in the company’s strategic plan by a commitment to sustainable growth.

To learn more about Helsinn Group please visit www.helsinn.com

About Xediton Pharmaceuticals

Xediton Pharmaceuticals is a privately-held pharmaceutical company with a focus on meeting the needs of patients, physicians and partners. Xediton Pharmaceuticals is committed to developing, partnering and making available new and established medicines to promote the health of Canadians. Located in the Greater Toronto Area, Canada, Xediton Pharmaceuticals has products in Oncology, Anti-Infectives, Pain, GI, Ophthalmology and CV and has built strong strategic alliances with Global and International Healthcare and pharmaceutical companies.

For more information, please visit www.xediton.com.

For more information:

Helsinn Group Media Contact:

Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Email: Info-hhc@helsinn.com

For more information, please visit www.helsinn.com and follow us on Twitter and LinkedIn

Xediton Contact:

George Gafrey

President

Tel: +1 905 286 9111

Email: info@xediton.com

For more information, please visit www.xediton.com and follow us on Twitter and LinkedIn